Locally advanced prostate cancer: A population-based study of treatment patterns - Abstract

Department of Surgery, Division of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center Urology Service, Department of Surgery Department of Radiation Oncology, Memorial Sloon-Kettering Cancer Center Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.



Study Type - Therapy (practice patterns) Level of Evidence 2b.

What's known on the subject? and What does the study add? The treatment of locally advanced prostate cancer varies widely even though there is level one evidence supporting the use of multimodality therapy as compared with monotherapy. This study defines treatment patterns of locally advanced prostate cancer within the United States and identifies predicators of who receives multimodality therapy rather than monotherapy.

To identify treatment patterns and predictors of receiving multimodality therapy in patients with locally advanced prostate cancer (LAPC).

The cohort comprised patients ≥66 years with clinical stage T3 or T4 non-metastatic prostate cancer diagnosed between 1998 and 2005 identified from the Surveillance, Epidemiology and End Results (SEER) cancer registry records linked with Medicare claims.  Treatments were classified as radical prostatectomy (RP), radiation therapy (RT) and androgen deprivation therapy (ADT) received within 6 and 24 months of diagnosis. We assessed trends over time and used multivariable logistic regression to identify predictors of multimodality treatment.

Within the first 6 months of diagnosis, 1060 of 3095 patients (34%) were treated with a combination of RT and ADT, 1486 (48%) received monotherapy (RT alone, ADT alone or RP alone), and 461 (15%) received no active treatment. The proportion of patients who received RP increased, exceeding 10% in 2005. Use of combined RT and ADT and use of ADT alone fluctuated throughout the study period. In all 6% of patients received RT alone in 2005. Multimodality therapy was less common in patients who were older, African American, unmarried, who lived in the south, and who had co-morbidities or stage T4 disease.

Treatment of LAPC varies widely, and treatment patterns shifted during the study period. The slightly increased use of multimodality therapy since 2003 is encouraging, but further work is needed to increase combination therapy in appropriate patients and to define the role of RP.

Written by:
Lowrance WT, Elkin EB, Yee DS, Feifer A, Ehdaie B, Jacks LM, Atoria CL, Zelefsky MJ, Scher HI, Scardino PT, Eastham JA.   Are you the author?

Reference: BJU Int. 2011 Nov 15. Epub ahead of print.
doi: 10.1111/j.1464-410X.2011.10760.x

PubMed Abstract
PMID: 22085255

UroToday.com Prostate Cancer Section